Mavenclad (cladribine) – risk of serious liver injury and new recommendations about liver function monitoring
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Medicine name |
Mavenclad
|
| Active substance |
Cladribine
|
| Therapeutic area (MeSH) |
Multiple Sclerosis
|
| Regulatory outcome |
Variation
|
| DHPC type |
Adverse event
|
| Human ATC code |
L04AA40
|
| Dissemination date |
14/02/2022
|